Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, a similar situation is playing out for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end ...

It’s a brand name for tirzepatide, which manufacturers also sell as a drug for type 2 diabetes under the name Mounjaro. Unlike others in its class, tirzepatide targets two hormones — glucagon ...

It also lifted guidance by $2 billion after the first quarter, citing booming demand for its tirzepatide products. In making the latest adjustment, Lilly cited its "prudent" rollout as it works to ...

Both tirzepatide (Mounjaro for T2D; Zepbound for obesity) and semaglutide have periodically been in shortage due to the ever-escalating demand for the drugs for weight loss. When a drug is ...

The Food and Drug Administration announced an official shortage of the active ingredients in these drugs in 2022, but on Oct. 2, 2024, the agency announced that the shortage has been resolved for the ...

Taylor Hill/WireImage Bunnie Xo is sharing an update on how she’s feeling on tirzepatide, joking she’s “never gonna be a sex symbol” because she only makes headlines for “how I wear diap ...

Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years. By law, that should have ...

Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity, rather than filing on the strength of its first, positive study.

For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's shortage was anything but welcome news. "I had an anxiety attack," said Maria ...

Injectable GLP-1 drugs including semaglutide and tirzepatide have been in shortage since 2022 because of their huge popularity. In the US, when the FDA declares that a drug is in shortage ...

This is incorrect. The five-year trial into the use of tirzepatide for people living with obesity will be funded entirely by the pharmaceutical company Lilly. The government will not be paying the ...